They have observed a correlation between the acquisition of BRCA1/2 reversion mutations and resistance to therapy, suggesting that these mutations may have potential utility in predicting the chemotherapy response of ovarian cancer and subsequently informing treatment strategies for this disease. This evidence concerns the gene BRCA1 and ovarian carcinoma.